Suppr超能文献

新生儿李斯特菌病的表现和结局:189 例前瞻性研究。

Neonatal Listeriosis Presentation and Outcome: A Prospective Study of 189 Cases.

机构信息

Institut Pasteur, Biology of Infection Unit, Paris, France.

Institut Pasteur, French National Reference Center and World Health Organization Collaborating Center Listeria, Paris, France.

出版信息

Clin Infect Dis. 2022 Jan 7;74(1):8-16. doi: 10.1093/cid/ciab337.

Abstract

BACKGROUND

Listeriosis is caused by the foodborne pathogen Listeria monocytogenes. It can present as a maternal-neonatal infection. We implemented a nationwide prospective cohort and analyzed the features of neonatal listeriosis.

METHODS

We studied all neonates born alive from mothers with microbiologically proven maternal-neonatal listeriosis enrolled from November 2009 to December 2017. We analyzed presentation, neonatal outcome at discharge, and predictors of severe presentation and outcome.

RESULTS

We studied 189 infants; 133 of 189 (70%) had abnormal clinical status at birth, including acute respiratory distress in 106 of 189 (56%). There were 132 of 189 (70%) infants who developed early-onset listeriosis and 12 of 189 (6%) who developed late-onset listeriosis; all presented with acute meningitis. There were 17 of 189 (9%) infants who had major adverse outcomes: 3%, (5 of 189) death; 6% (12 of 189), severe brain injury; and 2% (3 of 189), severe bronchopulmonary dysplasia. Fifteen of 17 infants were born <34 weeks of gestation (P < .0001 vs infants born ≥34 weeks of gestation). Maternal antimicrobial treatment ≥1 day before delivery was associated with a significant decrease in presentation severity for the infant, resulting in significantly fewer inotropic drugs, fluid resuscitation, and mechanical ventilation requirement (odds ratio, 0.23; 95% confidence interval, 0.09-0.51; P < .0001).

CONCLUSIONS

Antenatal maternal antimicrobial treatment is associated with reduced neonatal listeriosis severity, justifying the prescription of preemptive maternal antimicrobial therapy when maternal-fetal listeriosis is suspected. Neonatal outcome is better than reported earlier, and its major determinant is gestational age at birth.

CLINICAL TRIALS REGISTRATION

NCT01520597.

摘要

背景

李斯特菌病是由食源性病原体单核细胞增生李斯特菌引起的。它可表现为母婴感染。我们开展了一项全国性前瞻性队列研究,并分析了新生儿李斯特菌病的特征。

方法

我们研究了 2009 年 11 月至 2017 年 12 月期间所有确诊为母婴李斯特菌病的活产新生儿。我们分析了其临床表现、出院时的新生儿结局以及严重表现和结局的预测因素。

结果

我们研究了 189 例婴儿;其中 133 例(70%)在出生时存在异常临床状态,包括 189 例中的 106 例(56%)急性呼吸窘迫。189 例中有 132 例(70%)发生早发型李斯特菌病,189 例中有 12 例(6%)发生晚发型李斯特菌病;所有患儿均表现为急性脑膜炎。189 例中有 17 例(9%)婴儿出现严重不良结局:3%(5/189)死亡;6%(12/189)严重脑损伤;2%(3/189)严重支气管肺发育不良。17 例患儿中有 15 例(9%)出生于<34 周(P<0.0001 与出生于≥34 周的婴儿)。母亲在分娩前≥1 天接受抗菌治疗与婴儿临床表现严重程度显著降低相关,导致使用血管活性药物、液体复苏和机械通气的需求明显减少(比值比,0.23;95%置信区间,0.09-0.51;P<0.0001)。

结论

产前母亲抗菌治疗与新生儿李斯特菌病严重程度降低相关,因此在怀疑母婴李斯特菌病时,应预防性给予母亲抗菌治疗。新生儿结局优于之前报道的结果,其主要决定因素是出生时的胎龄。

临床试验注册

NCT01520597。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验